- About
FOSUN KAIROS -
About Fosun Kairos
Founded in 2017, Shanghai Fosun Kairos Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise under Fosun Pharma. Guided by our mission, "Cure fot Best Possible Life" we are committed to the research, development, industrialization, and commercialization of innovative cell therapy products for oncology. Our vision is to become the leader in cell and gene therapies.
- 10000
- 2017
- 2000
- 1000
-
10,000 m² CAR-T Industrialization Production Base
-
Established in 2017
-
Over 2000 m2 Cell Therapy R&D Center
-
Treated more than 1,000 patients with relapsed/refractory large B-cell lymphoma
YIKAIDAAxicabtagene Ciloleucel Injection
China's First CAR-T Cell Therapy Product Approved for Marketing
For the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
As of the end of December 2025, the drug has been included in the city tailored insurance programs of 119 provinces and cities and more than 90 commercial insurance programs, with 219 treatment centers registered.
Focused on
R&D of Immuno-Oncology
Cell Therapy Products
The Company's 2,000 m² cell therapy R&D center was established in early 2019. Our R&D pipeline includes multiple CAR-T/TCR-T candidates at the clinical stage, as well as early-stage innovative R&D projects. We collaborate with leading R&D institutions in the field of immuno-oncology, both domestically and internationally, to build a sustainable and innovative R&D pipeline.
Fosun Kairos News
-
-
Fosun Kairos Selected as a Pilot Enterprise for Trade Secret Protection Innovation in Shanghai, Earning Further Authoritative Recognition for Its IP Protection Efforts
-
-
Dual Indications Approved for Clinical Trials in MN and ALA! Fosun Kairos’ Autologous Dual-Target CAR-T FKC289 Accelerates Development
-
-
Innovation Frontier | Five Latest Achievements in China's Cell Therapy Accepted by ASGCT 2026, to Be Released Soon